https://scholars.lib.ntu.edu.tw/handle/123456789/584514
標題: | Androgen deprivation therapy did not increase the risk of Alzheimer's and Parkinson's disease in patients with prostate cancer | 作者: | Chung S.D. Lin H.C. Tsai M.C. Kao L.T. CHAO-YUAN HUANG Chen K.C. |
關鍵字: | Alzheimer's disease; Androgen deprivation therapy; Prostate cancer | 公開日期: | 2016 | 出版社: | Blackwell Publishing Ltd | 卷: | 4 | 期: | 3 | 起(迄)頁: | 481-485 | 來源出版物: | Andrology | 摘要: | Androgen deprivation therapy (ADT) has been the standard treatment for advanced prostate cancer for many decades. Although potential adverse effects of ADT have been reported, there are no empirical studies investigating the association between ADT and Alzheimer's disease. Therefore, this retrospective cohort study explored the relationship between the use of ADT and the subsequent risk of Alzheimer's disease in men with prostate cancer using a population-based database. We retrieved data from the "Taiwan Longitudinal Health Insurance Database 2000." The study included 1335 patients with prostate cancer and 4005 age-matched comparison patients without prostate malignancy. We then individually tracked each patient (n?=?5340) for a 5-year period to discriminate those who subsequently received a diagnosis of Alzheimer's disease. The Cox proportional hazard regression showed that the hazard ratio (HR) for Alzheimer's disease during the 5-year follow-up period for prostate cancer patients was 1.71 (95% confidence interval (CI)?=?0.90~3.25) over that of comparison patients. We further analyzed the hazard ratio for Alzheimer's disease and Parkinson's disease between prostate cancer patients who did and those who did not receive ADT, but we failed to observe a significant difference in the hazard ratio for both diseases during the 5-year follow-up period (adjusted HR?=?1.76, 95% CI?=?0.55~5.62, and HR?=?1.13, 95% CI?=?0.58~2.20, respectively). In conclusion, this study demonstrated that the use of androgen deprivation therapy in patients with prostate cancer was not associated with a higher risk of Alzheimer's and Parkinson's disease during the follow-up period. ? 2016 American Society of Andrology and European Academy of Andrology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84963763154&doi=10.1111%2fandr.12187&partnerID=40&md5=0dc644a0d787b9f54087f5b8880a7acd https://scholars.lib.ntu.edu.tw/handle/123456789/584514 |
ISSN: | 2047-2919 | DOI: | 10.1111/andr.12187 | SDG/關鍵字: | antiandrogen; antiandrogen; antineoplastic hormone agonists and antagonists; aged; Alzheimer disease; androgen deprivation therapy; Article; cohort analysis; controlled study; drug use; human; major clinical study; male; outcome assessment; Parkinson disease; priority journal; prostate cancer; retrospective study; risk assessment; Taiwan; Alzheimer disease; follow up; incidence; middle aged; Parkinson disease; prostate tumor; risk; very elderly; Aged; Aged, 80 and over; Alzheimer Disease; Androgen Antagonists; Antineoplastic Agents, Hormonal; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Parkinson Disease; Prostatic Neoplasms; Retrospective Studies; Risk; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。